KLRS — Kalaris Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1754068 ·
Last close
$1.43
Market Cap
$34.04M
52W High
$11.88
52W Low
$1.33
ADV30
88,929
Next earnings
—
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -11,811,000 -11,026,000 89,003,000 47,384,000 41,601,000
Jun 2026 0 — -12,386,000 -11,515,000 99,539,000 43,173,000 41,867,000
Mar 2026 0 — -11,833,000 -10,856,000 109,805,000 34,427,000 41,248,000
Dec 2025 0 — -10,801,000 -9,998,000 121,736,000 98,054,000 42,922,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,239,000
Investing CF
$-357,000
Financing CF
$45,593,000
CapEx
$-17,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.04
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-193,396,000
Inventory
—
Receivables
—
ST Investments
$35,472,000
EBIT TTM
$-43,395,000
Pretax Income TTM
$-43,395,000
Interest Exp TTM
$0
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -46,152,000 -43,438,000 121,736,000 42,922,000 78,814,000 -38,370,000
Dec 2024 0 -51,732,000 -69,167,000 6,162,000 102,778,000 -96,616,000 -20,670,000
Dec 2023 0 -13,464,000 -14,699,000 3,333,000 48,350,000 -45,017,000 -14,132,000
Dec 2022 0 -14,006,000 -15,485,000 3,899,000 34,171,000 -30,272,000 -9,779,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-44,263,000
OpCashFlow TTM
—
Assets (Latest)
$99,539,000
Forward EPS
$-1.70

Peers — same industry

TickerNameMarket CapLastDaily %
GNTA Genenta Science S.p.A. $33.03M $0.69 —
CVM CEL SCI CORP $32.54M $1.85 —
BKHA Black Hawk Acquisition Corp $35.93M $8.65 —
TIL Instil Bio, Inc. $36.62M $5.40 —
CRBU Caribou Biosciences, Inc. $36.81M $0.34 —

News headlines (Yahoo Finance, 1h cache)

Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-10 12:30 · Yahoo
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-31 12:00 · Yahoo
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
2026-07-20 12:00 · Yahoo
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
2026-07-17 11:00 · Yahoo
Kalaris Appoints Laurie Keating to Board of Directors
2026-07-06 20:05 · Yahoo
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
2026-06-23 12:00 · Yahoo
Kalaris to Present at Clinical Trials at the Summit 2026
2026-06-12 12:00 · Yahoo
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 12:00 · Yahoo
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 12:00 · Yahoo
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
2026-07-14 18:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.